Cite
HARVARD Citation
Panhaleux, M. et al. (2022). Anti–programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study. European journal of cancer. pp. 134-139. [Online].